Reporting both negative clinical trial results is as important as reporting positive results. However, pharmaceutical companies often bury negative results.

Fortunately (actually unfortunately because there were negative results) a Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel-based therapy failed to meet its endpoints, or has failed.

The study included 1,099 men with advanced prostate cancer who were randomly assigned in a 2:1 schedule to receive TAK-700. The primary end point was overall survival (OS). Key secondary end points which were to be analyzed only if the primary end point was achieved included radiographic progression-free survival